Cargando…

Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome

BACKGROUND: Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome (IBS) symptoms compared with placebo in double-blind randomized studies. However, few data are available from real-life clinical practice or from studies that used Rome IV criteria to diagnose IBS. AIM:...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabaté, Jean-Marc, Iglicki, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891724/
https://www.ncbi.nlm.nih.gov/pubmed/35317278
http://dx.doi.org/10.3748/wjg.v28.i7.732
_version_ 1784661958816956416
author Sabaté, Jean-Marc
Iglicki, Franck
author_facet Sabaté, Jean-Marc
Iglicki, Franck
author_sort Sabaté, Jean-Marc
collection PubMed
description BACKGROUND: Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome (IBS) symptoms compared with placebo in double-blind randomized studies. However, few data are available from real-life clinical practice or from studies that used Rome IV criteria to diagnose IBS. AIM: To assess the effect of B. longum 35624 on IBS severity and quality of life in a real-life setting. METHODS: From November 2018 to January 2020, 278 patients with IBS (according to Rome IV criteria) were enrolled in a prospective, open-label, multicenter observational study by private practice gastroenterologists to received one capsule of B. longum 35624 (10(9) colony-forming units) per day for 30 d. Participation in the study was independently proposed to patients during spontaneous consultations. Disease severity (assessed by the IBS severity scoring system) and patient quality of life (assessed by the IBS quality of life questionnaire) were compared between the inclusion visit (baseline) and the visit at the end of 30 d of treatment. The characteristics of patients were described at baseline. Continuous variables comparisons between inclusion and end-of-treatment visits were performed using the t-test and Kruskal-Wallis test. Categorical variables comparisons were performed using the χ2 test. RESULTS: A total of 233 patients, with a mean age of 51.4 years and composed of 71.2% women, were included in the study. Of these patients, 48.1% had moderate IBS and 46.4% had severe IBS. After a 30-d treatment period with one B. longum 35624 capsule per day, a significant decrease in IBS severity was observed compared to baseline (mean ± SD, IBS severity scoring system scores: 208 ± 104 vs 303 ± 81, P < 0.001) and 57% of patients moved to lower severity categories or achieved remission. The quality of life of patients was also improved by the treatment (IBS Quality of Life questionnaire score: 68.8 ± 20.9 vs 60.2 ± 20.5; P < 0.001) and 63.8% of patients were satisfied with the treatment. CONCLUSION: Thirty days of treatment with B. longum 35624 reduces disease severity and improves the quality of life of patients with IBS, particularly those with the most severe forms of IBS.
format Online
Article
Text
id pubmed-8891724
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-88917242022-03-21 Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome Sabaté, Jean-Marc Iglicki, Franck World J Gastroenterol Observational Study BACKGROUND: Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome (IBS) symptoms compared with placebo in double-blind randomized studies. However, few data are available from real-life clinical practice or from studies that used Rome IV criteria to diagnose IBS. AIM: To assess the effect of B. longum 35624 on IBS severity and quality of life in a real-life setting. METHODS: From November 2018 to January 2020, 278 patients with IBS (according to Rome IV criteria) were enrolled in a prospective, open-label, multicenter observational study by private practice gastroenterologists to received one capsule of B. longum 35624 (10(9) colony-forming units) per day for 30 d. Participation in the study was independently proposed to patients during spontaneous consultations. Disease severity (assessed by the IBS severity scoring system) and patient quality of life (assessed by the IBS quality of life questionnaire) were compared between the inclusion visit (baseline) and the visit at the end of 30 d of treatment. The characteristics of patients were described at baseline. Continuous variables comparisons between inclusion and end-of-treatment visits were performed using the t-test and Kruskal-Wallis test. Categorical variables comparisons were performed using the χ2 test. RESULTS: A total of 233 patients, with a mean age of 51.4 years and composed of 71.2% women, were included in the study. Of these patients, 48.1% had moderate IBS and 46.4% had severe IBS. After a 30-d treatment period with one B. longum 35624 capsule per day, a significant decrease in IBS severity was observed compared to baseline (mean ± SD, IBS severity scoring system scores: 208 ± 104 vs 303 ± 81, P < 0.001) and 57% of patients moved to lower severity categories or achieved remission. The quality of life of patients was also improved by the treatment (IBS Quality of Life questionnaire score: 68.8 ± 20.9 vs 60.2 ± 20.5; P < 0.001) and 63.8% of patients were satisfied with the treatment. CONCLUSION: Thirty days of treatment with B. longum 35624 reduces disease severity and improves the quality of life of patients with IBS, particularly those with the most severe forms of IBS. Baishideng Publishing Group Inc 2022-02-21 2022-02-21 /pmc/articles/PMC8891724/ /pubmed/35317278 http://dx.doi.org/10.3748/wjg.v28.i7.732 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Observational Study
Sabaté, Jean-Marc
Iglicki, Franck
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
title Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
title_full Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
title_fullStr Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
title_full_unstemmed Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
title_short Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
title_sort effect of bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891724/
https://www.ncbi.nlm.nih.gov/pubmed/35317278
http://dx.doi.org/10.3748/wjg.v28.i7.732
work_keys_str_mv AT sabatejeanmarc effectofbifidobacteriumlongum35624ondiseaseseverityandqualityoflifeinpatientswithirritablebowelsyndrome
AT iglickifranck effectofbifidobacteriumlongum35624ondiseaseseverityandqualityoflifeinpatientswithirritablebowelsyndrome